Search Result

Isoforms Recommended:	PI3Kδ

Results for "

PI3Kδ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (18) Apoptosis (40) ATM/ATR (1) Autophagy (12) Bacterial (2) Bcl-2 Family (1) Bcr-Abl (1) Biochemical Assay Reagents (1) Btk (1) c-Fms (1) c-Myc (1) Casein Kinase (8) Caspase (2) CD3 (1) CDK (3) Checkpoint Kinase (Chk) (1) Cytochrome P450 (1) DNA-PK (5) Drug Intermediate (1) Drug Isomer (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) Epigenetic Reader Domain (3) ERK (1) G Protein-coupled Receptor Kinase (GRK) (1) HDAC (6) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (2) IFNAR (1) Interleukin Related (2) Isotope-Labeled Compounds (3) Kinesin (1) Lipase (1) MEK (4) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Mitophagy (7) MMP (1) mTOR (20) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) Paraptosis (1) Parasite (2) PARP (1) PD-1/PD-L1 (1) PDK-1 (1) PERK (2) PI3K (192) PI4K (2) PPAR (1) PROTACs (3) Reactive Oxygen Species (ROS) (8) Reference Standards (17) SARS-CoV (2) VEGFR (1)
By Research Areas:	Cancer (155) Cardiovascular Disease (3) Infection (9) Inflammation/Immunology (46) Metabolic Disease (4) Neurological Disease (4)

By Targets:

Akt (18)

Apoptosis (40)

ATM/ATR (1)

Autophagy (12)

Bacterial (2)

Bcl-2 Family (1)

Bcr-Abl (1)

Biochemical Assay Reagents (1)

Btk (1)

c-Fms (1)

c-Myc (1)

Casein Kinase (8)

Caspase (2)

CD3 (1)

CDK (3)

Checkpoint Kinase (Chk) (1)

Cytochrome P450 (1)

DNA-PK (5)

Drug Intermediate (1)

Drug Isomer (1)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (1)

Epigenetic Reader Domain (3)

ERK (1)

G Protein-coupled Receptor Kinase (GRK) (1)

HDAC (6)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (2)

IFNAR (1)

Interleukin Related (2)

Isotope-Labeled Compounds (3)

Kinesin (1)

Lipase (1)

MEK (4)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Mitophagy (7)

MMP (1)

mTOR (20)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

Paraptosis (1)

Parasite (2)

PARP (1)

PD-1/PD-L1 (1)

PDK-1 (1)

PERK (2)

PI3K (192)

PI4K (2)

PPAR (1)

PROTACs (3)

Reactive Oxygen Species (ROS) (8)

Reference Standards (17)

SARS-CoV (2)

VEGFR (1)

By Research Areas:

Cancer (155)

Cardiovascular Disease (3)

Infection (9)

Inflammation/Immunology (46)

Metabolic Disease (4)

Neurological Disease (4)

194

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-102031

Linperlisib 1 Publications Verification YY-20394	PI3K	Inflammation/Immunology Cancer
Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of *PI3Kδ* extracted from patent WO 2015055071 A1, compound 10; has an IC₅₀ of 6.4 nM .

HY-109068

Parsaclisib 2 Publications Verification INCB050465; IBI-376	PI3K	Cancer
Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of *PI3Kδ, with an IC₅₀* of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies ^[3].

HY-17635

Leniolisib 1 Publications Verification CDZ173	PI3K	Inflammation/Immunology
Leniolisib (CDZ173) is a potent and selective *PI3Kδ* inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

HY-12644

Acalisib 1 Publications Verification GS-9820; CAL-120	PI3K	Cancer
Acalisib is a potent and selective *PI3Kδ* inhibitor with an IC₅₀ of 12.7 nM.

HY-12948

AMG319 1 Publications Verification	PI3K	Cancer
AMG319 is a potent and selective *PI3Kδ* kinase inhibitor with IC₅₀ of 18 nM.

HY-10111

TG100-115 2 Publications Verification	PI3K	Cardiovascular Disease Cancer
TG100-115 is a selective PI3Kγ/PI3Kδ inhibitor with IC₅₀s of 83 and 235 nM, respectively.

HY-50847

ZSTK474 15+ Cited Publications	PI3K Autophagy	Cancer
ZSTK474 is an ATP-competitive pan-class I *PI3K* inhibitor with IC₅₀s of 16 nM, 44 nM, 4.6 nM and 49 nM for PΙ3Κα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.

HY-135827

Roginolisib 1 Publications Verification MSC2360844; IOA-244	PI3K	Inflammation/Immunology Cancer
Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective *PI3Kδ* inhibitor, with an IC₅₀ of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases .

HY-109198

Zandelisib ME-401; PWT-143	PI3K Akt	Cancer
Zandelisib (ME-401) is a selective, orally active, non-covalent inhibitor of *PI3Kδ. Zandelisib can sustainably inhibit AKT* phosphorylation and downstream signaling pathways. Zandelisib can be used in the study of malignancies such as relapsed/refractory B-cell lymphoma .

HY-10110

IC-87114 3 Publications Verification	PI3K	Cancer
IC-87114 is a potent and selective *PI3Kδ* inhibitor with IC₅₀ of 0.5 μM.

HY-19535A

Nemiralisib GSK2269557 free base	PI3K	Cancer
Nemiralisib (GSK2269557 free base) is a potent and highly selective *PI3Kδ* inhibitor with a pK_i of 9.9.

HY-17645

Tenalisib 1 Publications Verification RP6530	PI3K	Cancer
Tenalisib (RP6530) is a novel, potent, and selective *PI3Kδ* and PI3Kγ inhibitor with IC₅₀ values of 25 and 33 nM, respectively.

HY-16754

Seletalisib 2 Publications Verification UCB5857	PI3K	Inflammation/Immunology
Seletalisib (UCB5857) is potent and selective *PI3Kδ* inhibitor with an IC₅₀ of 12 nM.

HY-176239

*PROTAC PI3Kδ* degrader-1**	PROTACs PI3K Akt Apoptosis Autophagy	Cancer
PROTAC PI3Kδ degrader-1 is a Lysine-targeted covalent *PI3Kδ* PROTAC degrader with a DC₅₀ of 3.98 nM. PROTAC PI3Kδ degrader-1 has a potent antiproliferative activity and selective PI3Kδ inhibition (IC₅₀: 8 nM). PROTAC PI3Kδ degrader-1 also significantly degrades p-AKT, induces cell cycle arrest in G1 phase and prompts cell apoptosis and autophagy. PROTAC PI3Kδ degrader-1 effectively inhibits the tumor growth in SU-DHL-6 xenograft mice model . Pink: PI3Kδ ligand (HY-169983); Blue: VHL ligase ligand (HY-112078); Black: linker (HY-W013381)

HY-12869

AZD-8835 1 Publications Verification	PI3K	Cancer
AZD8835 is a potent and selective inhibitor of PI3Kα and *PI3Kδ* with IC₅₀s of 6.2 and 5.7 nM, respectively.

HY-13514

TG 100713 2 Publications Verification	PI3K	Cancer
TG 100713 is an inhibitor of *PI3K, with IC₅₀s of 24, 50, 165, and 215 nM for PI3Kδ*, γ, α and β isoforms respectively .

HY-15280

GSK2292767	PI3K	Inflammation/Immunology
GSK2292767 is a potent and selective inhibitor of *PI3Kδ, with a pIC₅₀* of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease .

HY-115870

AZD8154	PI3K	Inflammation/Immunology
AZD8154 is a selective PI3Kγδ dual inhibitor. AZD8154 can suppress PI3Kγ and PI3Kδ signaling pathway activation. AZD8154 can be used for the researches of inflammation and immunology, such as asthma .

HY-131910A

*(R)-IHMT-PI3Kδ-372*	PI3K	Inflammation/Immunology
(R)-IHMT-PI3Kδ-372 (R-18) is a potent and selective *PI3Kδ* inhibitor with an IC₅₀ of 19 nM. (R)-IHMT-PI3Kδ-372 (R-18) can be used in chronic obstructive pulmonary disease (COPD) research .

HY-143404

PI3K-IN-30 3 Publications Verification	PI3K	Cancer
PI3K-IN-30 (compound 6d) is a potent *PI3K* inhibitor with IC₅₀s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively .

HY-17635A

Leniolisib phosphate 1 Publications Verification CDZ173 phosphate	PI3K	Inflammation/Immunology
Leniolisib (CDZ173) phosphate is a potent and selective *PI3Kδ* inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment.

HY-101921

PI3Kδ-IN-1	PI3K	Inflammation/Immunology
PI3Kδ-IN-1 is a potent, selective, and efficacious *PI3Kδ* inhibitor with an IC₅₀ of 1.7 nM.

HY-12340

ETP-46321	PI3K	Cancer
ETP-46321 is a potent and orally bioavailable PI3Kα and *PI3Kδ* inhibitor with K_iapps of 2.3 and 14.2 nM, respectively.

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC₅₀ values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .

HY-128333

PI3K/mTOR Inhibitor-4	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-4 is an orally active pan-class I *PI3K/mTOR* inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC₅₀ values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .

HY-10812

GNE-490	PI3K mTOR	Cancer
GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC₅₀s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC₅₀=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model .

HY-150638

PI3Kδ/γ-IN-3	PI3K Apoptosis	Cancer
PI3Kδ/γ-IN-3 (Compound 58) is a potent and orally active *PI3Kδ* and PI3Kγ dual inhibitor with IC₅₀s of 1 nM and 16 nM, respectively. PI3Kδ/γ-IN-3 induces tumor cell apoptosis and can be used for B-cell malignancies research .

HY-131910

*IHMT-PI3Kδ-372*	PI3K Cytochrome P450	Inflammation/Immunology
IHMT-PI3Kδ-372 is a potent and selective *PI3Kδ* inhibitor with an IC₅₀ of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research .

HY-15288

PI3kδ inhibitor 1	PI3K	Cancer
PI3kδ inhibitor 1 is a potent and selective *PI3Kδ* inhibitor with an IC₅₀ of 3.8 nM.

HY-W040417

Boc-L-cyclobutylglycine	PI3K	Others
Boc-L-cyclobutylglycine is a Boc-protected L-cyclic amino acid and synthetic intermediate in the preparation of purinyl quinazolinone *PI3Kδ* inhibitors .

HY-100694

GS-9901	PI3K	Inflammation/Immunology
GS-9901 is a highly selective and orally active *PI3Kδ* inhibitor with an IC₅₀ of 1 nM. GS-9901 has ≥100 fold selectivity for PI3Kα (IC₅₀ of 750 nM), PI3Kβ (IC₅₀ of 100 nM) and PI3Kγ (IC₅₀ of 190 nM). GS-9901 can be used for the study of rheumatoid arthritis .

HY-125376

PI3Kδ-IN-3	PI3K	Cancer
PI3Kδ-IN-3 (Compound 11) is a **PI3Kδ inhibitor (IC₅₀*: 9 nM). PI3Kδ-IN-3 inhibits B cell function. PI3Kδ-IN-3 has good pharmacokinetic properties .***

HY-143403

PI3K-IN-31	PI3K	Cancer
PI3K-IN-31 (Compound 6b) is a potent *PI3K* inhibitor with IC₅₀s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, PI3Kγ, and *PI3Kδ, respectively. PI3K-IN-31* has anticancer effects .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I *PI3K* and mTOR inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, *PI3Kδ* and mTOR, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .

HY-131345A

(S)-PI3Kα-IN-4	PI3K	Cancer
(S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC₅₀ of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, *PI3Kδ, and PI3Kγ, respectively. (S)-PI3K*α-IN-4 can be used for the research of cancer .

HY-17635S

Leniolisib-d5 CDZ173-d₅	Isotope-Labeled Compounds PI3K	Inflammation/Immunology
Leniolisib-d5 is a deuterated labeled Leniolisib . Leniolisib (CDZ173) is a potent and selective *PI3Kδ* inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

HY-122593

PI3Kδ-IN-5	PI3K	Cancer
PI3Kδ-IN-5 (compound 7n) is a highly potent and selective inhibitor of *PI3Kδ* with an IC₅₀ of 0.9 nM .

HY-175369

PI3Kδ-IN-25	PI3K Akt PD-1/PD-L1 Interleukin Related CD3	Inflammation/Immunology Cancer
PI3Kδ-IN-25 is an orally active selective *PI3Kδ* inhibitor (IC₅₀ = 2.1 nM). PI3Kδ-IN-25 has IC₅₀s of 272, 285, and 1171 nM for PI3Kα, PI3Kγ, and PI3Kβ, respectively. PI3Kδ-IN-25 inhibits AKT Ser473 phosphorylation, suppresses Treg cell proliferation, and downregulates PD-L1 expression in B16F10 cells. PI3Kδ-IN-25 exhibits anticancer effects in B16F10 melanoma and Lewis lung cancer mouse models by reducing tumor-infiltrating Treg cells and enhancing immune responses. PI3Kδ-IN-25 is potentially useful in the study of melanoma, lung cancer, and other cancers .

HY-109029

Dezapelisib INCB040093	PI3K	Cancer
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .

HY-174396

PI3Kδ/HDAC6-IN-1	PI3K HDAC Bcl-2 Family Caspase Reactive Oxygen Species (ROS) Apoptosis Histone Methyltransferase Microtubule/Tubulin	Cancer
PI3Kδ/HDAC6-IN-1 (Compound 22E) is an orally active and dual inhibitor of *PI3Kδ* and HDAC6 with IC₅₀ values of 2.4 nM and 6.2 nM, respectively. PI3Kδ/HDAC6-IN-1 exhibits potent antiproliferative effects on non-Hodgkin lymphoma (NHL) cells and possesses in vivo antitumor activity without significant toxicity. PI3Kδ/HDAC6-IN-1 arrests the cell cycle at the G0/G1 phase and induces apoptosis. PI3Kδ/HDAC6-IN-1 blocks the PI3K/AKT/mTOR signaling pathway and increases the acetylation levels of α-tubulin and histone H3 .

HY-108418

PI3Kδ-IN-15 1 Publications Verification	PI3K	Cancer
PI3Kδ-IN-15 (compound 6b) is a selective *PI3Kδ* inhibitor with an IC₅₀ of 0.5 nM for p110δ. PI3Kδ-IN-15 inhibits PI3Kδ with >30-fold higher potency than PI3Kγ, PI3Kβ, and PI3Kα .

HY-134472

PI3Kδ-IN-8	PI3K	Cancer
PI3Kδ-IN-8 is a potent, selective and orally active *PI3Kδ* inhibitor, with an IC₅₀ of 3.3 nM. PI3Kδ-IN-8 shows selectivity for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC₅₀=377.2, 241.6, 17.9 nM, respectively). PI3Kδ-IN-8 has anti-tumor activity .

HY-155232

PI3Kδ-IN-16	PI3K Apoptosis	Cancer
PI3Kδ-IN-16 is a potent and selective *PI3Kδ* inhibitor with an IC₅₀ value of 0.9 nM. PI3Kδ-IN-16 has a strong anti-proliferative effect on SU-DHL-6 cells, causing cell cycle arrest and inducing apoptosis. PI3Kδ-IN-16 tightly bins to PI3Kδ protein with a planar-shaped conformation. The kinase activity of PI3Kδ-IN-16 which is ~378-fold over PI3Kα, 412-fold over PI3Kβ, and 10-fold over PI3Kγ. PI3Kδ-IN-16 can be used for the study of hematologic malignancies .

HY-109068A

Parsaclisib hydrochloride 2 Publications Verification INCB050465 hydrochloride; IBI-376 hydrochloride	PI3K	Cancer
Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of *PI3Kδ, with an IC₅₀* of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies ^[3].

HY-144254

PI3Kδ-IN-10	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-10 is a highly potent and orally active *PI3Kδ* inhibitor with IC₅₀ of 2 nM. PI3Kδ-IN-10 robustly suppresses the downstream AKT pathway to induce subsequent apoptosis in hepatocellular carcinoma models .

HY-178445

PI3Kδ-IN-27	PI3K SARS-CoV	Infection
PI3Kδ-IN-27 is an *PI3Kδ* inhibitor with an IC₅₀ of 355.3 nM. PI3Kδ-IN-27 exhibits anti-SARS-CoV-2 activity. PI3Kδ-IN-27 can be used for the research of infection, such as COVID-19 .

HY-16122

CAL-130 Racemate	PI3K	Cancer
CAL-130 Racemate is the racemate of CAL-130. CAL-130 Racemate is a *PI3Kδ* inhibitor.

HY-12482

X-370	PI3K Apoptosis PDK-1 MEK Akt ERK	Cancer
X-370 is a *PI3Kδ* inhibitor (IC₅₀ = 7 nM). X-370 inhibits the survival of leukemia cells, inducing G1 arrest and apoptosis. X-370 blocks PDK1 binding and phosphorylation of MEK1/2, eliminating Akt and Erk1/2 signaling. X-370 can be used in research on B-cell acute lymphoblastic leukemia (B-ALL) .

HY-175734

PI3Kδ-IN-26	PI3K	Inflammation/Immunology
PI3Kδ-IN-26 (Compound 58) is a selective and orally active *PI3Kδ* inhibitor with an IC₅₀ of 14  nM. PI3Kδ-IN-26 significantly attenuates the inflammatory responses in house dust mite (HDM) induced chronic asthma mouse models. PI3Kδ-IN-26 can be used for inflammatory, autoimmune and hyperproliferative diseases research .

HY-142646

PI3Kδ-IN-9	PI3K	Cancer
PI3Kδ-IN-9 is a selective *PI3Kδ* inhibitor with an IC₅₀ value of 3.8 nM.

Cat. No.	Product Name	Target	Research Area

HY-W040417

Boc-L-cyclobutylglycine	PI3K	Others
Boc-L-cyclobutylglycine is a Boc-protected L-cyclic amino acid and synthetic intermediate in the preparation of purinyl quinazolinone *PI3Kδ* inhibitors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18085

Quercetin 195+ Cited Publications	Flavonols Classification of Application Fields Anti-aging Endocrine diseases Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Immune System Disorder Microorganisms other families Leguminosae Sunscreen Disease markers Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Source Classification Cancer	Reactive Oxygen Species (ROS) PI3K Autophagy Mitophagy Apoptosis
Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a *PI3K* inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-N0146

Quercetin dihydrate 190+ Cited Publications	Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	PI3K Apoptosis
Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a *PI3K* inhibitor with *IC₅₀s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K* γ, PI3K δ and PI3K β, respectively .**

HY-18085R

Quercetin (Standard)	Flavonols Structural Classification Endocrine diseases Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Immune System Disorder Microorganisms other families Leguminosae Disease markers Glycyrrhiza uralensis Fisch. Source Classification	Reactive Oxygen Species (ROS) Reference Standards PI3K Autophagy Mitophagy Apoptosis
Quercetin (Standard) is the analytical standard of Quercetin. This product is intended for research and analytical applications. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-N0078

Ginkgolic Acid (C13:0) Ginkgolic acid (13:0); Ginkgoneolic Acid; 6-Tridecylsalicylic acid	Infection Monophenols Ginkgoaceae Classification of Application Fields Ketones, Aldehydes, Acids Phenols Plants Ginkgo biloba Disease Research Fields Source Classification	Bacterial PI3K Parasite
Ginkgolic Acid (C13:0) (Ginkgoneolic Acid) is an anti-cariogenic agent and a *PI3Kδ* inhibitor (IC₅₀: 2.49 μM). Ginkgolic Acid (C13:0) exhibits antibacterial and anti-parasitic activities. Ginkgolic Acid (C13:0) can also inhibit mast cell degranulation (IC₅₀: 2.40 μM) ^[3].

HY-N0146R

Quercetin dihydrate (Standard)	Flavonols Structural Classification Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards PI3K Apoptosis
Quercetin (dihydrate) (Standard) is the analytical standard of Quercetin (dihydrate). This product is intended for research and analytical applications. Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC₅₀s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-N0078R

Ginkgolic Acid (C13:0) (Standard) Ginkgolic acid (13:0) (Standard); Ginkgoneolic Acid (Standard); 6-Tridecylsalicylic acid (Standard)	Structural Classification Monophenols Ginkgoaceae Ketones, Aldehydes, Acids Phenols Plants Ginkgo biloba Source Classification	Reference Standards Bacterial PI3K Parasite
Ginkgolic Acid (C13:0) (Standard) is the analytical standard of Ginkgolic Acid (C13:0) (HY-N0078). This product is intended for research and analytical applications. Ginkgolic Acid (C13:0) (Ginkgoneolic Acid) is an anti-cariogenic agent and a *PI3Kδ* inhibitor (IC₅₀: 2.49 μM). Ginkgolic Acid (C13:0) exhibits antibacterial and anti-parasitic activities. Ginkgolic Acid (C13:0) can also inhibit mast cell degranulation (IC₅₀: 2.40 μM) .

Cat. No.	Product Name	Chemical Structure

HY-18085S1

Quercetin-d3 1 Publications Verification
Quercetin-d₃ is the deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-18085S2

Quercetin-13C3
Quercetin- ¹³C₃ is the ¹³C-labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-17635S

Leniolisib-d5
Leniolisib-d5 is a deuterated labeled Leniolisib . Leniolisib (CDZ173) is a potent and selective *PI3Kδ* inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

HY-18085S

Quercetin-d5
Quercetin-d₅ is a deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-18085AS

Quercetin-d3 hydrate 1 Publications Verification
Quercetin-d3 hydrate is a deuterium labeled Quercetin hydrate (HY-18085A), a flavonoid which can stimulate recombinant SIRT1 and also a *PI3K* inhibitor with IC₅₀s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks